| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
N-Hexanoyl-L-homoserine lactone targets quorum sensing systems in Gram-negative bacteria. It binds to specific receptor proteins in bacteria, leading to the activation or repression of target genes involved in virulence, biofilm formation, and other population-dependent behaviors. The compound facilitates intercellular communication and information exchange between bacteria, allowing them to coordinate their behavior as a population.
|
|---|---|
| ln Vitro |
N-Hexanoyl-L-homoserine lactone demonstrates in vitro activity as a quorum sensing signaling molecule. It promotes lipid accumulation in algae. The compound's activity is typically assessed in reporter assays using bacterial strains engineered to respond to AHL signals, or in biofilm formation and virulence factor production assays.
|
| ln Vivo |
In vivo activity of N-hexanoyl-L-homoserine lactone has been suggested by its role in quorum sensing in bacterial infections. The compound mediates information exchange between eukaryotic plants and prokaryotic bacteria. Further in vivo studies are needed to evaluate its role in bacterial pathogenesis and its potential as a target for anti-virulence therapies.
|
| Enzyme Assay |
In vitro receptor binding assays for N-hexanoyl-L-homoserine lactone involve measuring its binding to quorum sensing receptors. Binding affinity can be assessed using surface plasmon resonance or radioligand binding assays. The compound's ability to activate quorum sensing pathways can be evaluated using reporter gene assays.
|
| Cell Assay |
In vitro cellular assays for N-hexanoyl-L-homoserine lactone involve treating bacterial cultures with varying concentrations of the compound and measuring quorum-sensing-regulated phenotypes such as bioluminescence, biofilm formation, or virulence factor production. Reporter strains containing lux or lacZ fusions to quorum-sensing promoters are commonly used.
|
| Animal Protocol |
In vivo animal experiments for N-hexanoyl-L-homoserine lactone are not extensively documented. If used in animal models of bacterial infection, typical protocols would involve administering the compound to infected animals to study its role in quorum sensing and bacterial pathogenesis. Further studies are needed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for N-hexanoyl-L-homoserine lactone are limited. The compound has a molecular weight of 199.25 and a molecular formula of C10H17NO3. Its amphipathic character allows partitioning into lipid bilayers. The compound is typically used in in vitro research settings. Its stability and metabolism in biological systems are areas of ongoing research.
|
| Toxicity/Toxicokinetics |
Toxicological data for N-hexanoyl-L-homoserine lactone are limited. As a bacterial signaling molecule, it is generally considered to have low toxicity in research settings. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
[1]. Frederike Stock,et al. Distinctive Growth and Transcriptional Changes of the Diatom Seminavis robusta in Response to Quorum Sensing Related Compounds. Front Microbiol. 2020 Jun 9;11:1240.
|
| Additional Infomation |
N-[(3s)-2-oxotetrahydrofuran-3-yl]hexanoamide is an N-acyl amino acid. It has been reported that N-[(3s)-2-oxotetrahydrofuran-3-yl]hexanoamide has been found in Azotobacter lipodilator, and relevant data are available for reference.
N-Hexanoyl-L-homoserine lactone (CAS#: 147852-83-3) has the molecular formula C10H17NO3 and a molecular weight of 199.25. It is a short-chain N-acyl homoserine lactone that functions as a quorum sensing signaling molecule in Gram-negative bacteria. The compound mediates intercellular communication and regulates gene expression in bacterial populations. |
| Molecular Formula |
C10H17NO3
|
|---|---|
| Molecular Weight |
199.25
|
| Exact Mass |
199.12
|
| CAS # |
147852-83-3
|
| PubChem CID |
10058590
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
434.0±34.0 °C at 760 mmHg
|
| Flash Point |
216.3±25.7 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.476
|
| LogP |
-0.04
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
14
|
| Complexity |
215
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C([C@]([H])(C([H])([H])C1([H])[H])N([H])C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)=O
|
| InChi Key |
ZJFKKPDLNLCPNP-QMMMGPOBSA-N
|
| InChi Code |
InChI=1S/C10H17NO3/c1-2-3-4-5-9(12)11-8-6-7-14-10(8)13/h8H,2-7H2,1H3,(H,11,12)/t8-/m0/s1
|
| Chemical Name |
N-[(3S)-2-oxooxolan-3-yl]hexanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (501.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0188 mL | 25.0941 mL | 50.1882 mL | |
| 5 mM | 1.0038 mL | 5.0188 mL | 10.0376 mL | |
| 10 mM | 0.5019 mL | 2.5094 mL | 5.0188 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
